Amgen Inc ((AMGN)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Amgen Inc. is currently recruiting participants for a Phase 2 study titled ‘A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With Small Cell Lung Cancer (SCLC) (DeLLphi-309)’. The primary objective is to evaluate the antitumor activity of Tarlatamab in patients with SCLC, aiming to provide insights into effective dosing regimens.
The study tests Tarlatamab, an investigational drug administered via intravenous infusion, across three different dosing regimens. This intervention targets enhancing treatment efficacy for SCLC patients.
The study employs an interventional design with randomized allocation and a parallel intervention model. It is open-label, meaning no masking is involved, and its primary purpose is treatment-focused.
Key dates include the actual start date of February 26, 2025, with the last update submitted on August 19, 2025. These dates are crucial for tracking the study’s progress and anticipated milestones.
The study’s outcomes could significantly influence Amgen’s stock performance by potentially strengthening its oncology portfolio. Positive results may enhance investor confidence, especially in the competitive cancer treatment market.
The study is ongoing, with further details available on the ClinicalTrials portal.